tirzepatide obstructive sleep apnea fda approval 2024 Zepbound (tirzepatide) is now FDA-approved as the first medication for (OSA) in adults with obesity. It works by reducing body weight, which helps improve breathing during Huge news: FDA has approved

GLP-1 receptor agonists do not directly attack muscle tissue

Full data is expected in mid-2026: which would put an FDA decision on the drug into late 2027 or 2028

Data from the agency's Adverse Event Reporting System (FAERS) shows more than 280 of those were associated with compounded drugs said to contain semaglutide, although the figure may be an undercount because some reports were submitted by patients who may not recognize or report that their medicine is a compounded drug

There is no universally correct day

However, the absence of burping does not mean the medication is not working, as individual experiences with side effects vary considerably